Treehugger :打乒乓球能改善帕金森手颤!日本研究

2020-04-30 卢芳 中国循环杂志

“我的手经常发抖,越是不动越抖得厉害,干活拿东西的时候反倒不抖了。遇到生人或激动的时候也抖得厉害,睡着了就不抖了。”

“我的手经常发抖,越是不动越抖得厉害,干活拿东西的时候反倒不抖了。遇到生人或激动的时候也抖得厉害,睡着了就不抖了。”

帕金森病患者常常会这样说。除了静止性震颤,患者还可出现运动迟缓、肌强直和平衡差等,严重影响生活质量。

怎样改变?

近日一项日本研究发现,中轻度帕金森病患者打打乒乓球,可明显改善这些症状。

研究显示,中轻度帕金森病患者每周一次乒乓球训练,进行3~6个月后,语言、写字、穿衣、起床和行走都得到了明显改善。

此外,患者在面部表情、姿势、僵硬度、运动迟缓及手部震颤等方面均显著改善。

比如,颈部肌肉僵硬度,试验后比试验前评分改善了1分。

研究者表示,打乒乓球这种有氧运动,有助于改善手眼协调性,增强反射能力和刺激大脑。这项研究虽小但结果颇受鼓舞,准备在更大人群中进一步证实。

这项研究共纳入12例平均年龄为73岁的中轻度帕金森病患者,平均确诊帕金森病7年。

历史来源:
Melissa Breyer. Ping pong holds promise for improving Parkinson’s symptoms.Treehugger. February 26, 2020

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1054107, encodeId=7981105410efc, content=希望有更多的数据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f255526204, createdName=我思故我在2, createdTime=Thu Sep 23 11:09:29 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647495, encodeId=f4c0164e495a9, content=<a href='/topic/show?id=6ca1233e5d4' target=_blank style='color:#2F92EE;'>#乒乓球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23375, encryptionId=6ca1233e5d4, topicName=乒乓球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bfb23436095, createdName=ligang4447, createdTime=Thu Oct 01 09:09:04 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021685, encodeId=b9b8202168541, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 13 12:09:04 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294542, encodeId=8dd91294542d2, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat May 02 01:09:04 CST 2020, time=2020-05-02, status=1, ipAttribution=)]
    2021-09-23 我思故我在2

    希望有更多的数据支持

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1054107, encodeId=7981105410efc, content=希望有更多的数据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f255526204, createdName=我思故我在2, createdTime=Thu Sep 23 11:09:29 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647495, encodeId=f4c0164e495a9, content=<a href='/topic/show?id=6ca1233e5d4' target=_blank style='color:#2F92EE;'>#乒乓球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23375, encryptionId=6ca1233e5d4, topicName=乒乓球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bfb23436095, createdName=ligang4447, createdTime=Thu Oct 01 09:09:04 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021685, encodeId=b9b8202168541, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 13 12:09:04 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294542, encodeId=8dd91294542d2, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat May 02 01:09:04 CST 2020, time=2020-05-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1054107, encodeId=7981105410efc, content=希望有更多的数据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f255526204, createdName=我思故我在2, createdTime=Thu Sep 23 11:09:29 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647495, encodeId=f4c0164e495a9, content=<a href='/topic/show?id=6ca1233e5d4' target=_blank style='color:#2F92EE;'>#乒乓球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23375, encryptionId=6ca1233e5d4, topicName=乒乓球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bfb23436095, createdName=ligang4447, createdTime=Thu Oct 01 09:09:04 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021685, encodeId=b9b8202168541, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 13 12:09:04 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294542, encodeId=8dd91294542d2, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat May 02 01:09:04 CST 2020, time=2020-05-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1054107, encodeId=7981105410efc, content=希望有更多的数据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f255526204, createdName=我思故我在2, createdTime=Thu Sep 23 11:09:29 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647495, encodeId=f4c0164e495a9, content=<a href='/topic/show?id=6ca1233e5d4' target=_blank style='color:#2F92EE;'>#乒乓球#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23375, encryptionId=6ca1233e5d4, topicName=乒乓球)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bfb23436095, createdName=ligang4447, createdTime=Thu Oct 01 09:09:04 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021685, encodeId=b9b8202168541, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Wed Jan 13 12:09:04 CST 2021, time=2021-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294542, encodeId=8dd91294542d2, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat May 02 01:09:04 CST 2020, time=2020-05-02, status=1, ipAttribution=)]

相关威廉亚洲官网

JAMA Neurol:亚洲人群帕金森病相关遗传风险因素研究

本次在亚洲人群的PD相关基因风险全基因组关联研究发现了2个新的基因位点,以及9个先前发现的欧洲人群位点,这一研究证实了亚洲和欧洲个体在PD遗传危险因素方面的异同,对亚洲人群风险分层和精确医学具有潜在

JN:新发现:帕金森治疗的新进展:光遗传学+深部脑刺激

最近美国杜克大学的一项新研究表明,以光遗传学为基础的深部脑刺激可以缓解大鼠中的帕金森症状。

这12类药物会引起「帕金森」,别误诊了!

帕金森病(PD)又名震颤麻痹,是一种以中脑黑质多巴胺神经元进行性退变为主、多系统受累的缓慢进展的中老年神经系统变性疾病。

Cell Death and Dis:适用于研究帕金森病神经退行性变的新模型

帕金森病的一个主要特征是黑质致密带(SNpc)多巴胺能神经元的丧失。但这种相对选择性的神经退行性变的病理生理机制尚不明确,因此需要研究多巴胺能神经元功能障碍的实验系统。而诱导多能干细胞(iPSC)向多巴胺能神经元分化的实验也为获得人源性的多巴胺能神经元提供了宝贵的来源。但就目前可用的实验方案而言,将人源hiPSC诱导成多巴胺能神经元的产量也有所不同。在本研究中,研究人员开发了一种基于HBA启动子驱

2019年帕金森病研究十大新进展

帕金森氏病影响超过1%的人口,是仅次于阿尔茨海默氏症的第二大神经退行性疾病。根据世界卫生组织(WHO)的数据,它影响了全球600万人,这一数字到2030年可能达到1200万人。帕金森病主要影响称为黑质(substantia nigra)的大脑区域中的神经元。这些神经元负责产生多巴胺(一种用于在整个大脑中传输信号的化学信使),并负责传递计划和控制身体运动的信息。帕金森病特点是运动和认知问题,但这

美国FDA批准帕金森病新药上市,显著缩短“关闭期”时间

今日,Neurocrine Biosciences公司宣布,美国FDA已批准其口服药物Ongentys(opicapone)作为左旋多巴/卡比多巴的辅助疗法,治疗经历“关闭”期